生物制药公司Palvella Therapeutics(股票代码:PVLA)迎来重要研发里程碑——其获得快速通道认定的创新药Qtorin™雷帕霉素,已正式启动针对临床显著性血管角化瘤的二期Lotu临床试验,并完成首位患者给药。该突破性进展标志着公司在罕见皮肤病治疗领域迈出关键一步。
生物制药公司Palvella Therapeutics(股票代码:PVLA)迎来重要研发里程碑——其获得快速通道认定的创新药Qtorin™雷帕霉素,已正式启动针对临床显著性血管角化瘤的二期Lotu临床试验,并完成首位患者给药。该突破性进展标志着公司在罕见皮肤病治疗领域迈出关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.